Randomized, double-blind, dose-comparison study of glatiramer acetate in relapsing–remitting MS
- 20 March 2007
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology
- Vol. 68 (12), 939-944
- https://doi.org/10.1212/01.wnl.0000257109.61671.06
Abstract
Objective: To evaluate the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg daily vs the approved 20-mg formulation in relapsing–remitting multiple sclerosis.This publication has 19 references indexed in Scilit:
- Glatiramer acetate reduces the proportion of new MS lesions evolving into “black holes”Neurology, 2001
- European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosisAnnals of Neurology, 2001
- Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disabilityNeurology, 1998
- Inflammatory central nervous system demyelination: Correlation of magnetic resonance imaging findings with lesion pathologyAnnals of Neurology, 1997
- Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosisNeurology, 1995
- Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- A Pilot Trial of Cop 1 in Exacerbating–Remitting Multiple SclerosisThe New England Journal of Medicine, 1987
- New diagnostic criteria for multiple sclerosis: Guidelines for research protocolsAnnals of Neurology, 1983
- Multiple sclerosis: Trial of a synthetic polypeptideAnnals of Neurology, 1982
- Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis: Preliminary reportJournal of the Neurological Sciences, 1977